Cardiac safety remains the leading cause of drug development discontinuation. AnaBios has developed a human cardiomyocyte-based model that has the potential to provide a predictive preclinical approach for simultaneously predicting drug-induced inotropic and pro-arrhythmia risk.
PUBLICATION: Frontiers in Physiology (2017)
AUTHORS: Nathalie Nguyen, William Nguyen, Brynna Nguyenton, Phachareeya Ratchada, Guy Page, Paul E. Miller, Andre Ghetti and Najah Abi-Gerges